Addiction Neuroscience

Binge drinking is characterized by an initial bout of rapid, high-vigor alcohol intake (front-loading) followed by a prolonged period of lower-rate "maintenance" drinking, yet the circuit mechanisms that generate and regulate these phases remain unclear. Here, we develop a systems-level computational model that links the structure of binge drinking to interactions among medial prefrontal cortex (mPFC), insula, striatum, and ventral tegmental area (VTA). The model consists of cortical Seek (mPFC) and Go (insula) populations that form a mutually excitatory loop, a SetPoint population that integrates striatal activity as an internal estimate of effort/consumption, ventral (nucleus accumbens, NAc) and dorsal (dorsolateral striatum, DLS) striatal populations, and a dopaminergic VTA population providing transient reward-prediction signaling. Using a firing-rate formalism with noisy dynamics, we reproduce the canonical two-phase binge pattern and show that: (i) the PFC-insula loop acts as a bistable module that initiates and sustains front-loading; (ii) striato-cortical feedback to the Setpoint population controls the timing of the transition from front-loading to maintenance without altering its vigor; and (iii) the amplitude of the VTA dopamine transient selectively scales front-loading intensity. Sensitivity analyses identify PFC-insula connectivity, VTA-to-NAc modulation, and striato-cortical feedback as key parameters that bifurcate two-phase drinking into regimes with abolished or persistent front-loading. These findings provide a mechanistic framework for interpreting binge-like alcohol intake in terms of identifiable circuit motifs and generate testable predictions for targeting mPFC-insula-striatal-VTA interactions in alcohol use disorder.

4-hydroxytamoxifen (4-OHT) is commonly used to facilitate activity-dependent recombination in neurons. Here we show that one dose of 4-OHT devalues alcohol, contexts, and tastants, indicating that experimental designs using 4-OHT should control for its aversiveness. Further, reactivation of 4-OHT-responsive neurons causes conditioned taste avoidance. An activity screen coupled with graph theoretical analysis identifies candidate brain areas mediating these effects. We suggest these areas could be therapeutic targets for treating addiction.

Chronic ethanol consumption produces long-lasting effects on the brain that contribute to persistent behavioral changes. This has been modeled in animals using the chronic intermittent ethanol (CIE) paradigm, which induces escalation of consumption and alterations in affective and cognitive behavior. While this model has been well characterized in male subjects, the effects of CIE in females and long-term effects that persist beyond the acute withdrawal remain relatively underexplored. Here, female C57BL/6J mice were exposed to four weeks of chronic intermittent ethanol (CIE) vapor to induce dependence. Following CIE, mice were evaluated for physiological tolerance to ethanol and alterations in anxiety-like behaviors and memory processing. Using the ethanol responsivity battery (ERB) assay to assess physiological tolerance, we found blunted responsiveness to the intoxicating effects of ethanol in the CIE-exposed females, indicating heightened ethanol tolerance that persists beyond the acute withdrawal phase. A cohort underwent behavioral testing following CIE to characterize changes in anxiety-like behavior, exploration, and memory across abstinence. In early abstinence (<5 days post-CIE), CIE-exposed females showed increased exploratory behavior compared with Air controls. After one week of abstinence, CIE-exposed females displayed impaired object recognition memory. CIE-exposed females also showed increased anxiety-like behavior at protracted abstinence time points, exhibiting hyponeophagia in the novelty-suppressed feeding test at 2 weeks post-CIE. In addition, following cued fear conditioning, we found reduced extinction recall at 4 weeks post-CIE. Together, this work indicates that chronic alcohol exposure leads to increased alcohol tolerance and distinct, persistent alterations in memory and anxiety-like behavior in female mice.

Following cocaine self-administration, male and female rats received daily semaglutide during a 30-day abstinence period before cue- and cocaine-induced reinstatement tests. Semaglutide attenuated cue-induced reinstatement and cocaine-induced stereotypy, although operant responding was elevated following cocaine priming. These findings support further investigation of semaglutide as a treatment for cocaine use disorder.

In the KARE trial, 96 adults with severe alcohol use disorder, abstinent following detoxification, were randomised in a 2x2 factorial design to 3 weekly infusions of ketamine (0.8 mg/kg) or saline, each combined with mindfulness-based psychological support (PS) or alcohol psychoeducation (PE). We re-expressed the trial data on endpoints acceptable to regulators and compared the most and least intensive arms. Across pooled weeks 17-24, ketamine plus PS gave 78.5% versus 57.8% days abstinent (difference, 20.7 percentage points; P = .032); adjusted for baseline, the difference at weeks 21-24 was 26.9 percentage points (P = .011). At weeks 21-24, 50.0% versus 26.1% had no heavy drinking days (P = .127). Relative reductions in heavy drinking days were 55% in KARE, against 25%, -17%, 46% and 35% reported for naltrexone, exenatide, semaglutide and pemvidutide. These post hoc differences, measured 4 to 6 months after a 4 week course ended, are of magnitude similar to agents requiring continuous administration.

Genetics shape cocaine behavior and abuse liability, but the underlying neurophysiological effects remain understudied. In male C57BL/6J, B6129SF2/J, and DO/J mice, we report conserved and divergent cocaine induced neuroplasticity in the accumbens shell following 5 days of cocaine and 10 to 14 days of abstinence.

Alcohol use disorders are heritable, and large-scale genome-wide association studies have recently identified novel genetic loci that are correlated with alcohol consumption and problematic alcohol use. One such gene is Slc39a8, which encodes the ion transporter ZIP8, responsible for cellular import of zinc and other metals. Slc39a8 is highly pleiotropic, and a common missense variant has been associated with decreased problematic alcohol use. Here, we used Slc39a8 heterozygous (HET) knockout mice and their wild type (WT) littermates to characterize the effects of reduced gene function on two models of voluntary alcohol consumption (drinking in the dark and intermittent access two-bottle choice), and anxiety- and depression-like behavior. We found that HET mice consumed less alcohol than WT in the intermittent access two-bottle choice procedure. No evidence was found for genotypic differences in baseline locomotor activity, anxiety-like, or depression-like behavior in the open field and forced swim tests. Slc39a8 mRNA expression and alcohol metabolism experiments confirmed decreased brain expression of Slc39a8 in HET mice and unchanged alcohol metabolism. Basal and post-alcohol measurement of zinc levels showed that HET mice after ethanol exposure had lower zinc concentrations in the liver and higher concentrations in blood than WT animals. Analysis of the spatial distribution of multiple trace metals in the brains of naive Slc39a8 HET and WT mice using Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICP-MS) showed region-specific genotypic differences in levels of zinc and iron. These results provide evidence for a direct role of Slc39a8 in ethanol consummatory behavior that does not appear to be due to metabolism, affective state, or locomotor activity. Moreover, we confirm that this animal model shows tissue- and brain region-specific alterations in zinc levels, highlighting potential mechanisms for future study.

Background: Deficits in inhibitory control are considered a central feature of alcohol use disorder (AUD), yet behavioral and neuroimaging findings have been inconsistent. One potential explanation is the marked heterogeneity of AUD, which encompasses multiple symptom dimensions that may differ in their underlying neurocognitive mechanisms. In this study, we investigated whether behavioral and neural markers of inhibitory control are associated with specific DSM-5 AUD symptom domains. Methods: A total of 589 participants (432 with non-treatment seeking AUD, 157 controls) completed a Stop-Signal Task (SST) during fMRI. Associations between DSM-5 symptom domains (impaired control over alcohol use, risky use, social problems, physical dependence) and SST performance, inhibition-related brain activation, and alcohol consumption were examined. Real-life drinking behavior was additionally assessed over 12 months using ecological momentary assessment (EMA). Results: Greater impaired control symptom severity was associated with poorer performance on go trials and diminished post-error slowing during SST. At the neural level, higher impaired control symptom severity was associated with reduced activation across fronto-insular, parietal, cingulate, supplementary motor, and cerebellar regions. In contrast, other symptom domains showed little to no associations with inhibition-related behavioral or neural measures. Higher impaired control symptom severity was associated with greater alcohol consumption across questionnaire-based and EMA-based assessments. Conclusions: In this large cohort, altered behavioral performance and recruitment of inhibition-related brain regions in the SST was selectively linked to impaired control symptoms. These findings highlight the importance of symptom-based approaches for understanding heterogeneity in addiction and may inform the development of more targeted interventions.

Pavlovian conditioned stimuli can compromise goal-directed behavior, particularly when they conflict with the required instrumental response. Previous research linked an increased impact of such Pavlovian-to-instrumental transfer (PIT) interference to risky drinking and alcohol dependence. However, it remained unclear whether the observed behavioral and neural alterations generalize to the substantially larger population of non-treatment-seeking individuals with predominantly mild-to-moderate alcohol use disorder (AUD) and to other substances like nicotine. We therefore studied 200 participants from the general population who were stratified by AUD and smoking status before completing a single-lever PIT task during functional imaging. PIT interference was measured as the difference in error rates between incongruent PIT trials, characterized by conflicts of Pavlovian and instrumental stimuli, and congruent trials. Associations with AUD and smoking status, as well as dimensional associations of behavioral PIT interference and neural responses to PIT conflicts with substance-related measures, were examined. As expected, participants with AUD showed greater PIT interference and reduced conflict-related activation in the lateral prefrontal, dorsomedial prefrontal, and anterior cingulate cortex than participants without AUD. The magnitude of these alterations also correlated with higher AUD severity and alcohol consumption, while being independent of smoking status and other smoking-related measures. These findings suggest that enhanced PIT interference generalizes to the broader AUD population but may not extend to other substances like nicotine. They further implicate a reduced recruitment of prefrontal control networks during PIT conflicts as a potential mechanism underlying enhanced PIT interference in AUD and its association with clinically relevant outcome measures.

Objective To evaluate the association of early addiction consultation with withdrawal pharmacotherapy and complications in hospitalized patients with alcohol withdrawal. Methods Retrospective single-center cohort of adult hospitalizations with alcohol withdrawal (diagnosis code or CIWA-Ar [&ge;]10 within 24 hours) from July 2020 to January 2026. Exposure was an addiction consult service order within 24 hours of arrival, compared with no or later consultation. Primary outcomes were intensive care unit (ICU) transfer after the first 24 hours and delirium tremens or withdrawal seizure not present on admission. Process outcomes included phenobarbital and thiamine administration within 24 hours and benzodiazepine dose in the first 48 hours. Secondary outcomes included length of stay and 30-day death or return to hospital. Results Of 4,663 hospitalizations, 1,379 (29.6%) received early consultation. After adjustment, early consultation was associated with lower odds of ICU transfer (odds ratio [OR] 0.73; 95% CI 0.54-0.99) and fewer episodes of delirium tremens (risk difference -1.09 per 100; -1.45 to -0.73), with no significant difference in withdrawal seizure. Early consultation was associated with phenobarbital (OR 1.57; 1.32-1.86) and thiamine (OR 1.23; 1.07-1.41) within 24 hours, higher 48-hour lorazepam-equivalent dose (ratio of geometric means 1.44; 1.32-1.57), shorter stays (ratio 0.92; 0.88-0.97), and lower odds of 30-day death or return to hospital (OR 0.78; 0.66-0.91). Conclusions Early addiction consultation was associated with earlier, more intensive withdrawal pharmacotherapy, lower odds of ICU transfer, and fewer episodes of delirium tremens, although the complication associations were sensitive to cohort definition.

Approximately 30% of U.S. adolescents have consumed alcohol, and earlier onset is associated with faster escalation and greater risk of adult alcohol use disorder. Predicting not only who will initiate drinking but also when could enable more timely and targeted prevention. Existing machine-learning approaches have largely classified drinking status or predefined trajectory classes, requiring fully observed outcomes and often excluding adolescents who remain abstinent at last follow-up. Many also rely on neuroimaging or small, hand-selected feature sets, limiting scalability. We developed a stacked-encoder survival framework for predicting drinking-onset timing from baseline clinical data alone. The framework compresses 1,582 clinical features using an unsupervised denoising autoencoder and re-embeds them with FocalTab, a TabPFN encoder fine-tuned with focal loss; the encoders are then frozen for survival modeling using a neural Cox or random survival forest head. Among 661 NCANDA adolescents who were non-drinkers at baseline, 495 initiated drinking within six years. The stacked representation outperformed single-encoder and raw-feature models, achieving an Uno C-index of 0.7654 and time-dependent AUC of 0.8274. Focal-loss encoding outperformed cross-entropy encoding, while SHAP identified alcohol expectancies, substance access, and community prevention engagement among the most influential predictors. Unsupervised clustering further identified five biotypes with a monotonic gradient in mean time to onset (4.30 to 2.86 years) and differential limbic and thalamic neuroimaging phenotypes. These findings support the feasibility of scalable, clinically based prediction of drinking-onset timing and data-driven adolescent risk stratification.

Importance: Preventing substance use disorder (SUD) is a top public health priority, but clinical practice currently lacks validated prognostic tools to identify risk before the onset of heavy use/problems. Objective: To determine whether models can predict SUD using genetic, behavioral, and environmental factors and to evaluate performance across substance types (alcohol, cannabis, tobacco), sex, and genetic similarity groups. Design: This prognostic study developed and validated a multi-domain risk model using data from four longitudinal cohorts (The National Longitudinal Study of Adolescent to Adult Health, Avon Longitudinal Study of Parents and Children, The Collaborative Study on the Genetics of Alcoholism, and FinnTwin12) with follow-up from early adolescence into young adulthood. Setting: Population-based and family-based samples from the United States, United Kingdom, and Finland. Participants: The analysis included participants with available genomic and behavioral data. The cohorts represented a spectrum of risk, ranging from nationally representative community samples to high-risk populations. Exposure(s) (for observational studies): Predictors included polygenic scores for substance use-related phenotypes and 10 established early-life behavioral and environmental risk factors. Main Outcome(s) and Measure(s): The outcomes were a diagnosis of moderate-to-severe SUD based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and positive and negative predictive value. Results: A total of 16,362 participants were included in the study (54.7% female; mean [SD] age 26.73 [3.36]). Genetic similarity group composition was 70.4% European, 16.8% African, 9.8% admixed American, 2.2% East Asian, and 0.7% South Asian. SUD prevalence was 22.0%. The integrated model achieved an AUC of 0.78 for predicting any SUD, with a sensitivity of 69% and a positive predictive value of 45%. Performance was comparable for specific substances (AUC range 0.74-0.82) and across genetic similarity groups (AUC range 0.61-0.82). The model demonstrated higher AUC in females compared with males. Conclusions and Relevance: Findings highlight the potential utility of an SUD prediction model to inform clinicians and patients about risk for developing a SUD.

Chronic heavy alcohol use shifts brain metabolism from glucose toward acetate utilization. Sudden decreases in acetate following alcohol cessation in individuals with alcohol use disorder (AUD) may create an energetic imbalance that contributes to craving and withdrawal. A recent randomized study found that, compared with a standard American (SA) diet, a ketogenic diet (KD) during alcohol detoxification reduced withdrawal severity and craving and increased ketones and glutamate in the dorsal anterior cingulate cortex. These findings suggest that ketones may support metabolic adaptation during alcohol withdrawal, but the effects of altered brain metabolism on neural dynamics and alcohol cue reactivity remain unknown. Here, we used a control theoretic approach to test whether shifts in cerebral energy substrate utilization influence large-scale network dynamics through altered information flow. We analyzed fMRI cue-reactivity scans collected after one, two, and three weeks of inpatient treatment during presentation of alcohol, food, and neutral cues. Whole-brain effective connectivity was estimated using Shannon transfer entropy applied to whole brain atlas-aligned fMRI time series. Assuming neural activity flow along effective connections, we identified distinct shifts in the state-transition landscape in participants receiving the KD compared with the SA diet. Increases in serum {beta}-hydroxybutyrate (BHB) were associated with changes in state-transition landscape organization, which were in turn associated with reduced cue-induced alcohol craving. These findings link metabolic adaptation to large-scale neural dynamics and clinically relevant behavior and suggest that cerebral energy substrate availability may shape behavior by altering the organization of large-scale neural dynamics.

Background. Regulatory pressure to avoid confusingly similar drug names appears to have pushed manufacturers to coin more distinctive proprietary names, but no one has quantitatively analyzed this trend. Objective. To determine whether proprietary drug names became more orthographically distinctive (unusual in spelling) over time. Methods. We examined 1,321 US Food and Drug Administration (FDA) new molecular entity (NME) names (1985-2024), 2,769 FDA Orange Book trade names (1982-2026), 177,337 US pharmaceutical trademarks (1980-2026), and 1,273 generic names (1982-2025). Compared to prior names (including those already marketed) and ordinary English, we scored each name's character trigram (three-letter sequence) surprisal (statistical unexpectedness) and its edit-distance similarity to the closest existing names. Linear regression tested time trends, controlling for name length. Results. Mean NME trigram surprisal rose in every decade between the 1980s and 2020s, from 7.21 to 8.50 nats (natural-logarithm units, higher meaning less predictable), an 18% increase (b = 0.038, p < .001, R2 = 0.34). Half of 2020s names (7% in the 1980s) contained a letter sequence found in no common English word (e.g., Jesduvroq, Omvoh). Nearest-neighbor similarity fell after the early 1990s. Trademark data showed the same trend (b = 0.016, p < .001). Generic names showed a weaker trend (b = 0.011, R2 = 0.063). Conclusions. Over four decades, drug names became more orthographically distinctive, consistent with namespace crowding, deliberate efforts to avoid confusing names, and branding strategy. Because unfamiliar letter sequences can introduce other error pathways, increased distinctiveness does not necessarily imply improved safety.

Background Cocaine use disorder (CUD) is estimated to be 50% heritable, yet few genetic variants have been robustly associated with risk. During January 2021 to June 2024, cocaine was involved in 30% of U.S. overdose deaths. Identifying genetic contributors to CUD could inform diagnostics and treatments. The missing heritability may stem from small sample sizes, models that inadequately account for small-effect common variants, and the exclusion of large-effect structural variants like copy number changes. Epistasis likely contributes but remains challenging to detect genome-wide. Results We focused on epistasis and haplotypes rather than individual SNPs by applying the custom correlation coefficient in BlocBuster to construct allele networks from eQTL SNPs. Testing these regulatory haplotype networks for association with cocaine use in 7,826 individuals with opioid use disorder identified 12 significant associations across two ancestries. For one haplotype, raw genotyping array intensity data revealed a copy number increase at the CYP2D6 locus in individuals of European ancestry. In a subcohort of individuals who co-use cocaine and heroin (i.e., speedball), two haplotypes were also significantly associated with HIV infection. One of these involved GPR75, whose ligand, CCL5 (RANTES), is shared with CCR5, a coreceptor for HIV entry. Conclusions Our findings, integrated with long-read human pan-genomes, support a model in which non-functional copies of CYP2D6 disrupt dopaminergic, glutamatergic, and kynurenine pathways in the brain, contributing to cocaine use severity. The association of additional haplotypes with HIV status in speedball users highlights the genetic contribution to comorbid risk in high-exposure populations.

Genome-wide association studies (GWAS) have identified numerous loci associated with substance use disorders (SUDs). To connect common genetic variation to cell type- and region-specific gene expression and chromatin accessibility, we examined the enrichment of genetic liability for several SUDs (alcohol, cannabis, tobacco, and opioid use disorders) and substance consumption phenotypes (drinks per week, cannabis ever-use, and cigarettes per day) in available single-nucleus RNAseq data spanning 10 brain regions and snATACseq data spanning 42 brain regions. Significant cell-type enrichment after multiple testing corrections was observed only for drinks per week and tobacco use disorder in the snRNAseq data and for cannabis use disorder and problematic alcohol use in snATACseq data. Across both transcriptomic and chromatin accessibility annotations, enrichment patterns were concentrated in excitatory neuronal populations, particularly upper layer intratelencephalic neurons, amygdala excitatory neurons, and regionally resolved striatal medium spiny neuron subtypes. Drinks per week, problematic alcohol use, and cannabis use disorder showed enrichment values that were significantly correlated within cell-type across snRNAseq and snATACseq, suggesting convergent biological signals across independent single-nucleus modalities. These findings implicate chromatin-mediated expression differences in specific excitatory neuronal populations as potential mediators of SUD genetic liability and highlight the value of integrating transcriptomic and chromatin accessibility data for characterising the neurobiology of addiction.

Circadian clock genes in the striatum modulate alcohol drinking behavior in female mice, but the underlying synaptic mechanisms remain unknown. Medium spiny neurons (MSNs) of the striatum express D1- or D2-type dopamine receptors, which are differentially modulated by alcohol. Here we used whole-cell patch-clamp recordings to examine how deletion of the clock gene Bmal1 affects spontaneous excitatory postsynaptic currents (sEPSCs) in electrophysiologically identified D1 and D2 neurons of the female mouse dorsomedial striatum (DMS). Prior intermittent access to alcohol increased sEPSC amplitude in putative D1 neurons of wildtype mice without affecting sEPSC frequency, and this increase was accompanied by greater dendritic branching and complexity in biocytin-filled D1 MSNs. Bmal1 knockout had the opposite effect in D1 neurons, reducing sEPSC amplitude in both alcohol-exposed and alcohol-naive animals. In D2 neurons, alcohol produced only a non-significant trend toward increased sEPSC amplitude in wildtype mice, but a significant increase in Bmal1 knockout mice. Thus, local disruption of Bmal1 appears to block the alcohol-induced enhancement of sEPSCs in D1 neurons while unmasking a similar enhancement in D2 neurons. These findings may help explain how Bmal1 deletion in the DMS reduces alcohol consumption in female mice.

Background: Risk of recurrent overdose is elevated following non-fatal overdose (NFOD) survival; timely interventions may reduce this risk. The specific role of mental health care in reducing recurrence is relatively underexplored, and post-overdose care has seldom been examined for sex differences. This study examined sex differences in the association between mental health-related primary care contacts following NFOD and overdose recurrence risk among people in British Columbia (BC) with a documented depression diagnosis history. Methods: This was a nested case-control study using linked administrative health data from the Provincial Health Services Authority Platform for Analytics and Data. The source cohort (n=7,022) comprised BC residents with a history of a documented depression diagnosis between 2010-2014 and at least one NFOD between 2015-2024. Cases experienced a recurrent overdose within one year of their index overdose; controls were selected using incidence density sampling. Exposures were the presence and number of mental health related primary care contacts in the 30- or 90-day window following the index overdose. Conditional logistic regression models were used to estimate adjusted incidence rate ratios (aIRRs) and confidence intervals (CI), overall and by sex. Secondary analyses were conducted using psychiatrist contacts. Results: Mental-health related primary care contact rates were low, with only 16.3% and 28.1% of the cohort with any contact within 30 and 90 days, respectively. Mental health-related primary care contacts were more strongly associated with reduced recurrence risk in the 30-day window (any contact aIRR: 0.57 [CI: 0.46-0.71]) than in the 90-day window (aIRR: 0.78 [CI: 0.65-0.94]). Any contact within 30 days was more strongly associated with lower recurrence risk among males (aIRR: 0.53 [CI: 0.39-0.72]) than among females (aIRR: 0.67 [CI: 0.50-0.91]), whereas associations between the number of contacts and recurrence risk were similar for males and females. Any psychiatrist contact within 30 days was more strongly associated with lower recurrence risk among females (aIRR: 0.50 [CI: 0.34-0.73]) than males (aIRR: 0.70 [0.52-0.95]). Discussion: Mental health-related care contacts shortly following NFOD were associated with lower overdose recurrence risk among people with a documented depression diagnosis history, with modest sex differences that varied by provider type. Low rates of contacts overall suggest gaps in access to care following NFOD, particularly among males. Further research on sex differences in post-overdose care are warranted.

Drugs of abuse produce lasting adaptations in the striatum. A prominent theory holds that the early reinforcing effects of cocaine preferentially engage the ventral striatum, and repeated cocaine use recruits dorsal striatal systems associated with habitual drug-related behavior. However, this transition has largely been conceptualized on the population level, obscuring how it is implemented within individual neurons and how repeated drug exposure reorganizes drug responsivity within these circuits. Here, we used single-cell calcium imaging to examine ventral and dorsal striatal responses to acute and repeated cocaine exposure in mice. Cocaine broadly suppressed neuronal activity throughout the ventral and dorsal striatum. However, repeated exposure produced opposing changes in cocaine-modulated neurons across the ventral-dorsal axis. The cocaine-activated population was reduced ventrally while expanding dorsally. Unique to dorsal striatum, repeated cocaine engendered two distinct features of activity: 1) Cocaine-activated cells had weak baseline coupling with the surrounding neuronal population and 2) The emergence of a subpopulation of neurons exhibiting regular, slow rhythmic activity in response to cocaine. Thus, repeated cocaine effects reflect a change in how the circuit is organized rather than simply how strongly it is engaged. This organization may allow cocaine to engage patterns of dorsal striatal activity that are largely absent under baseline conditions, creating a circuit state that becomes increasingly specific to the presence of the drug.

Background: Social difficulties in alcohol use disorder (AUD) have been linked to alterations in social cognition, including increased egocentric bias. Psychedelics such as psilocybin have been proposed to modulate self-related processing, but their effects on specific socio-cognitive mechanisms remain unclear. Methods: In this randomized controlled pilot study, recently detoxified individuals with AUD with persistent depressive symptoms completed a visual perspective-taking task before and after a psilocybin session (25 mg dose vs active placebo 1 mg psilocybin). Results: The 25 mg psilocybin group showed a significant reduction in egocentric bias and egocentric superiority on reaction times, with no effect on altercentric bias nor on accuracy. Between-group comparisons confirmed greater reductions in the high-dose relative to the low-dose group. The high-dose group reported more intense subjective psychedelic experiences, and greater subjective intensity was associated with lower egocentric superiority in accuracy. Conclusions: These findings provide preliminary evidence that psilocybin may selectively reduce egocentric interference in individuals with AUD, suggesting a decrease in egocentricity rather than enhanced sensitivity to others. Although replication in larger samples is needed, reduced egocentricity may represent one mechanism through which psilocybin influences social cognition in AUD. Clinical trial registration: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06235411, NCT06235411.